Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Cerep Partner on Drug Discovery Tools

NEW YORK (GenomeWeb News) – PerkinElmer today announced that it has signed a co-marketing agreement with Cerep to provide custom drug discovery tools and services to customers.
 
Under the agreement, PerkinElmer will exclusively market Cerep’s target screening and profiling services to its customers. The firms also will jointly promote PerkinElmer’s assay technologies and Cerep’s high-throughput screening and profiling services to the drug discovery market.
 
PerkinElmer said that the alliance provides its customers with an option to work with a single vendor throughout the entire drug discovery process.
 
“This agreement represents the latest step in our strategy to build the most comprehensive offering in biochemical and cellular screening for drug discovery,” PerkinElmer President and CEO Robert Friel said in a statement.
 
The firm rapidly expanded its cellular analysis and screening business early in 2007 with the acquisitions of Evotec Technologies, Euroscreen Products, and Improvision.
 
Paris-based Cerep specializes in custom binding, cellular, and tissue assay services. It also has developed the BioPrint pharmacoinformatics platform.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.